Ipamorelin has been reported to stimulate growth hormone release with greater selectivity than earlier secretagogues in the models studied.
What is not established
A hormone-release signal is a pharmacodynamic observation, not a clinical outcome. No long-term human outcome or safety data exist.
Supporting sources (3)
Ipamorelin for the treatment of postoperative ileus after bowel resection: a randomised, placebo-controlled phase 2 trial
Beck DE, Sweeney WB, McCarter MD, et al. · International Journal of Colorectal Disease · 2014 · n = 114
- Population
- Adults undergoing partial bowel resection
- Endpoint
- Time to first tolerated solid food
- Route
- Intravenous
- Quantity as reported
- 0.03 mg/kg per administration, twice daily
- Frequency
- Twice daily from postoperative day 1 until discharge or day 7
- Duration
- 1 weeks
Result. 25.3 hours versus 32.6 hours for placebo. The difference was not statistically significant (p=0.15).
Adverse events. No significant safety signal over the short treatment period.
Limitations. This is the only human randomised trial of ipamorelin at any dose, it is a negative result, and the amount used, about 2 mg per administration intravenously for a 70 kg adult, is roughly ten times what is sold for subcutaneous use.
Ipamorelin as a selective growth hormone secretagogue: pharmacology literature
Multiple · Various endocrinology and pharmacology journals · 2018
- Population
- Animal pharmacology; limited early human pharmacodynamic work
- Endpoint
- Growth hormone release and selectivity versus cortisol and prolactin
- Route
- Intravenous and subcutaneous
- Quantity as reported
- Reported in early pharmacology work; no established human protocol
- Frequency
- Varies
Result. Reported to release growth hormone with greater selectivity than earlier secretagogues in the models studied.
Adverse events. Not established in sustained human use.
Limitations. A pharmacodynamic signal is not a clinical outcome. No adequate long-term human outcome or safety data.
Peptide therapeutics in musculoskeletal medicine: a review of the evidence
Multiple · American Journal of Sports Medicine · 2026
- Population
- Review of the published literature on peptides marketed for musculoskeletal use
- Endpoint
- State of the evidence for musculoskeletal indications
Result. Concludes that no clinical data support the use of GHK-Cu for musculoskeletal conditions, that CJC-1295 and ipamorelin synergy data is murine only, that tesamorelin has no supporting orthopaedic evidence, and that for the class generally the indications, amounts, frequency and duration of treatment remain unknown.
Adverse events. Not an outcome of the review.
Limitations. A narrative review, not a meta-analysis. It is catalogued because it is the most recent peer-reviewed statement of how thin this evidence base is, and because it is the counterweight to every vendor page that implies otherwise.
Last evidence review: 2026-08-23